Moderna Shares Plummet 25% After Unauthorized Release of Cancer Vaccine Data

Shares of Moderna plummeted by as much as 25% on Thursday following the unauthorized release of partial data on its cancer vaccine in development with Merck.

Despite the leak, the full data released later that day showed promising results for patients, meeting or exceeding Wall Street's expectations. The personalized vaccine, known as intismeran autogene, combines Moderna's technology with Merck's immunotherapy Keytruda to combat melanoma.

When administered alongside Keytruda, the vaccine significantly reduced the risk of cancer recurrence or death in certain melanoma patients by 42%. Additionally, it lowered the likelihood of cancer spreading to distant parts of the body or death by 38% compared to using just Keytruda.

The data also revealed that nearly 82% of patients who received the personalized cancer vaccine alongside Keytruda remained alive without their melanoma returning at two years post-treatment, a notable improvement over the 70% survival rate achieved with Keytruda alone.

The personalized cancer vaccine developed by Moderna and Merck has been shown to have a significant impact when combined with Keytruda, a widely used immunotherapy treatment for melanoma.

One notable advantage of this combination is its relatively mild side effects compared to other cancer treatments. Injection-site pain was the most common adverse reaction reported in patients who received the vaccine alongside Keytruda.

The phase 3 trial results are set to be presented at the European Society for Medical Oncology conference, but they have already been leaked ahead of time. The data suggests that the combination therapy is highly effective in preventing melanoma recurrence and death.

Analysts have weighed in on the implications of the leaked data, with some noting that investors' expectations may have been overly optimistic. Despite this, several experts agree that the results are overall positive and demonstrate a clinically meaningful reduction in the risk of recurrence or death.

The targeted vaccine's potential to treat various forms of cancer has generated significant interest among oncologists and investors, who see it as a possible breakthrough treatment in this field.

Merck and Moderna are currently conducting trials across different tumor types, including non-small cell lung cancer, bladder cancer, and renal cell carcinoma. These studies aim to demonstrate the vaccine's efficacy beyond its initial success in treating a specific type of skin cancer. While some progress has been made, experts agree that more work is needed to fully understand the vaccine's potential.

The approach taken by Moderna involves targeting specific mutations within each patient's tumor, rather than using a one-size-fits-all method. This personalized strategy aims to train the immune system to recognize and attack unique cancer markers, which can then be paired with other treatments like Keytruda to enhance its effectiveness.

A successful commercialization of this vaccine could provide Moderna with a crucial new product in its pipeline, complementing its existing vaccines for Covid-19, flu, and respiratory syncytial virus.

Moderna's shares have plummeted despite positive results from its cancer vaccine data. This downturn may be attributed to excessively high expectations surrounding the company's performance. The latest data release has provided a boost of confidence for upcoming studies involving kidney and bladder cancers.

UBS analysts have been closely following Moderna's progress and have expressed optimism about the vaccine's prospects. They attribute the negative market reaction to unrealistic expectations rather than disappointing results. As a result, investors may be overreacting to what appears to be encouraging data from the company.

The contrast between Moderna's performance and that of its rival, Merck, is striking. While shares of Merck fell by about 1% on Thursday, it has still managed to climb nearly 41% this year. This divergence highlights the intense scrutiny under which Moderna operates, with investors eagerly awaiting every development in the company's pipeline.